At mAbxience, we believe that the journey from the lab bench to the global market defines our commitment to advancing healthcare. With a proven track record in biosimilar production, we leverage cutting-edge technologies, an expert team, and a strategic global network to develop and deliver high-quality medicines to patients worldwide.
Innovation at every step
mAbxience’s pipeline reflects our mission to expand patient access to life-changing therapies. Since 2010, we have successfully developed and commercialized two biosimilars now available in over 100 countries and have six currently under development.
Through a “quality by design” approach, we integrate upstream and downstream innovations, ensuring our biosimilars meet the highest standards of quality, safety, and efficacy. Exhaustive comparability testing and rigorous clinical trials, guided by global regulatory standards, underscore our dedication to excellence.
Building the foundation
Our in-house R&D platform provides the agility and control needed to drive every stage of biopharmaceutical development. From cell line creation to formulation and manufacturing processes, our team’s expertise ensures seamless transitions from concept to production.
mAbxience’s strong internal intellectual property (IP) and regulatory teams play a critical role, navigating complex approval pathways and maintaining freedom to operate across markets. With proven leadership in scientific submissions and reviews, we consistently meet and exceed regulatory expectations.
Delivering on a worldwide scale
Strategic alliances are central to mAbxience’s ability to reach over 100 markets with more than 30 global and regional partners. These collaborations, combined with an efficient supply chain and state-of-the-art manufacturing facilities, enable us to adapt to diverse regulatory and commercial environments. This flexibility ensures the consistent delivery of affordable, high-quality medicines to healthcare systems worldwide.
A continuous journey
Biopharmaceutical development is a meticulous journey, requiring innovation at every stage—from upstream cultivation and downstream purification to comprehensive quality control. mAbxience’s fully integrated approach ensures we meet global demand for biosimilars while maintaining the highest quality standards.
As 2024 comes to an end, we remain committed to our mission of improving healthcare accessibility through world-class manufacturing, and strong partnerships. With a growing pipeline and proven expertise, mAbxience continues to bridge the gap between the lab and the market, bringing hope and healing to patients around the world.
Ready to collaborate? Partner with mAbxience for your biopharmaceutical projects and benefit from our expertise and end-to-end CDMO solutions. Visit our website or contact us at contact@mabxience.com to learn more.
